Nisa Investment Advisors LLC Has $61,000 Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

Nisa Investment Advisors LLC raised its holdings in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 44.6% in the third quarter, Holdings Channel reports. The institutional investor owned 5,441 shares of the biopharmaceutical company’s stock after buying an additional 1,679 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Dynavax Technologies were worth $61,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other large investors also recently modified their holdings of DVAX. GAMMA Investing LLC increased its position in shares of Dynavax Technologies by 175.5% during the third quarter. GAMMA Investing LLC now owns 2,645 shares of the biopharmaceutical company’s stock valued at $29,000 after purchasing an additional 1,685 shares during the period. Algert Global LLC bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $140,000. Sanctuary Advisors LLC bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $182,000. XTX Topco Ltd bought a new stake in shares of Dynavax Technologies during the second quarter valued at approximately $184,000. Finally, Duality Advisers LP bought a new stake in shares of Dynavax Technologies during the first quarter valued at approximately $227,000. 96.96% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

DVAX has been the topic of a number of research reports. The Goldman Sachs Group lowered their price objective on Dynavax Technologies from $20.00 to $15.00 and set a “neutral” rating on the stock in a research report on Thursday, August 8th. HC Wainwright restated a “buy” rating and set a $29.00 price objective on shares of Dynavax Technologies in a research report on Tuesday, October 15th.

Dynavax Technologies Stock Performance

Shares of NASDAQ:DVAX opened at $12.02 on Friday. The business’s fifty day moving average price is $11.13 and its two-hundred day moving average price is $11.24. Dynavax Technologies Co. has a fifty-two week low of $9.74 and a fifty-two week high of $15.01. The stock has a market capitalization of $1.58 billion, a price-to-earnings ratio of 109.28 and a beta of 1.34. The company has a debt-to-equity ratio of 0.35, a current ratio of 14.18 and a quick ratio of 13.18.

Dynavax Technologies (NASDAQ:DVAX) last announced its quarterly earnings results on Tuesday, August 6th. The biopharmaceutical company reported $0.08 earnings per share for the quarter, beating analysts’ consensus estimates of $0.06 by $0.02. Dynavax Technologies had a return on equity of 2.76% and a net margin of 6.88%. The firm had revenue of $73.80 million for the quarter, compared to analysts’ expectations of $76.92 million. During the same period in the prior year, the business posted $0.03 earnings per share. As a group, analysts predict that Dynavax Technologies Co. will post 0.16 EPS for the current fiscal year.

Dynavax Technologies Profile

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.